Effects of estrogen and estrogen-progesteron on serum nitric oxide metabolite concentrations in post-menopausal women

Journal of Endocrinological Investigation

Volumn 31, Issue 10, 2008, Pages 877-881

  Bednarek Tupikowska, G ^a   Tworowska Bardzinska U ^a   Tupikowski, K ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Estrogen and estrogen progesteron therapy; Menopause; Nitric oxide

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; ESTRADIOL; ESTROGEN; FOLLITROPIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PROGESTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME SYNTHESIS; ESTROGEN BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PREMENOPAUSE; TREATMENT DURATION;

EID: 58649121990     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346435     Document Type: Article

References (43)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998, 280: 605-13.
2. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288: 321-33.
3. Bhavnani BR, Strickler RC, Menopausal hormone therapy. J Obstet Gynaecol Can 2005, 27: 137-62.
4. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002, 288: 872-81.
5. Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits-an attempt to interpret the Women's Health Initiative results. Gynecol Endocrinol 2006, 22: 303-17.
6. Mueck AO, Seeger H. Estrogens acting as cardiovascular agents: direct vascular actions. Curr Med Chem Cardiovasc Hematol Agents 2004, 2: 35-42.
7. Collins P. Vascular effect of hormones. Maturitas 2001, 38: 45-50.
8. Kurtay G, Ozmen B, Erguder I. A comparison of effect of sequential transdermal administration versus oral administration of estradiol plus norethisterone acetate on serum NO level in postmenopausal women. Maturitas 2006, 53: 32-8.
9. Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon RO 3rd. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997, 96: 2795-801.
10. Chambliss KL, Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocrine Rev 2002, 23: 665-86.
11. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43: 109-42.
12. Gryglewski RJ. Prostacyclin and nitric oxide. Acta Hematol Pol 1994, 25 (Suppl 2): 75-81.
13. Cohen RA. The role of nitric oxide and other endothelium-clerived vasoactive substances in vascular disease. Prog Cardiovasc Dis 1995, 38: 105-28.
14. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipids peroxidation. FEBS Lett 1987, 210: 37-9.
15. Yagi K, Komura S. Inhibitory effect of female hormones on lipid peroxidation. Biochem Int 1986, 13: 1051-5.
16. Bednarek-Tupikowska G, Tupikowski K, Bidzińska B, et al. Serum lipid peroxides and total antioxiclant status in postmenopausal women on hormone replacement therapy. Gynecol Endocrinol 2004, 19: 57-63.
17. Wambi-Kiéssé CO, Katusic ZS. Inhibition of copper/zinc superoxide clismutase impaires NO0 mediated endothelium-dependent relaxations. Am J Physiol 1999, 276: H1043-8.
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18: 499-502.
19. Gidez LI, Miller GJ, Burstein M, Slagle S, Eder HA. Separation and cluantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982, 23: 1206-23.
20. Cooke JP, Tsao P. Ceilular mechanisms of atherogenesis and the effect of nitric oxide. Curr Opinion Cardiol 1992, 7: 799-804.
21. Tinker AC, Wallace AV. Selective inhibitors of inducible nitric oxide synthase: potential agents for treatment of inflammatory diseases? Curr Top Med Chem 2006, 6: 77-92.
22. Chizyński K. Znaczenie upośledzenia śródbłlonkowej produkcji tlenku azotu w patogenezie chorób ukłladu krażenia. Cześć I. Forum Kardiologów 1999, 3: 6-9.
23. Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Chn Endocrinol Metab 1997, 82: 388-94.
24. Majmuclar NG, Robson SC, Ford GA. Effects of the menopause, gender and estrogen replacement therapy on vascular nitric oxide activity. J Clin Endocrinol Metab 2000, 85: 1577-83.
25. Cicinelli E, Ignarro LJ, Lograno M, Galantino P, Balzano M, Schonauer LM. Circulating levels of nitric oxide in fertile women in relation to the menstrual cycle. Fertil Steril 1996, 66: 1036-8.
26. Jokela H, Dasticar P, Rontu R, et al. Effects of long-term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function. J Clin Endocrinol Metab 2003, 88: 4348-54.
27. Kesim MD, Aydin Y, Erdemir M, Atis A. Nitric oxide in postmenopausal women taking three different HRT regimens. Maturitas 2005, 10: 52-7.
28. Balci H, Altunyurt S, Acar B, Fadiloglu M, Kirkali G, Onvural B. Effects of transdermal estrogen replacement therapy on plasma levels of nitric oxide and plasma lipids in postmenopausal women. Maturitas 2005, 50: 289-93.
29. Ylikorkala O, Cacciatore B, Paakkari I, Tikkanen MJ, Viinikka L, Toivonen J. The long-effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril 1998, 69: 883-8.
30. Barnes JF, Farish E, Rankin M, Hart DM. Acomparison of the effects of two continuous HRT regimens on cardiovascular risk factors, Atherosclerosis 2002, 160: 185-93.
31. Hwang J, Mack WJ, Xiang M, Sevanian A, Lobo RA, Hodis HN. Long-term effect of estrogen replacement on plasma nitric oxide levels: results from the estrogen in the prevention of atherosclerosis trial (EPAT). Atherosclerosis 2005, 181: 375-80.
32. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthase by sex hormones. Proc Natl Acad Sci U S A 1994, 91: 5212-6.
33. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett 1995, 360: 291-3.
34. Simoncini T, Fornari L, Mannella P, et al. Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system: interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase. Steroids 2002, 67: 935-9.
35. Liao JK, Shin WS, Lee WY, Clark SL. Oxidised low-density lipoproteins decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995, 270: 319-24.
36. Wang MY, Liehr JG. Induction by estrogens of lipid peroxidation and lipid peroxide-derived malonaldehyde-DNA adducts in male Syrian hamsters: role of lipid peroxidation in estrogen-induced kidney carcinogenesis. Carcinogenesis 1995, 16: 1941-5.
37. Lind L. Lipids and enclothelium-clependent vasocilation: a review. Lipids 2002, 37: 1-15.
38. Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 1997, 82: 388-94.
39. Doursout MF, Chelly JE. Effects of estrogen in the regulation of nitric oxide pathway during development of hypertension in rats. Proc West Pharmacol Soc 2002, 45: 49-52.
40. Hughes MN. Relationships between nitric oxide, nitroxyl ion, nitrosonium cation and peroxynitrite. Biochim Biophys Acta 1999, 1411: 263-72.
41. Leal-Hernández M, Albellán-Alemán J, Carbonell-Meseguer LF, Díaz-Fernández J, Garcia-Sanchez FA, Martinez-Selva JM. Influence of the presence of hot flashes during menopause on the metabolism of nitric oxide. Effects of hormonal replacement treatment. Med Clin (Barc) 2000, 114: 41-5.
42. Rosselli M, Imthum B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17-beta estradiol and norethisterone acetate. A two-year follow-up study. Hypertension 1995, 25: 848-53.
43. Bednarek-Tupikowska G, Tworowska U, Jecrychowska I, et al. Effects of estradiol and estroprogestin on erythrocyte antioxidative enzyme system activity in postmenopausal women. Clin Endocrinol (Oxf) 2006, 64: 463-8.